AAPP 2025 industry supported symposia (continuing education) and showcases (non-continuing education) are programs developed for educational purposes. All industry-supported programming at AAPP 2025 is designed for the psychiatric pharmacist and is included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation, and each one provides 1.0 contact hours of ACPE credit.
Attendees! A few reminders:
|
Industry Symposia with ACPE Credit |
Breakfast will be served from 7:00-7:15 AM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: Existing psychotropic nomenclature (e.g., “atypical antipsychotics”) falls quite short of being accurate or useful. Here, Dr. Joseph Goldberg will take a deep dive into the issues with current nomenclature -including the impact on clinician behavior, patient outcomes, and stigma. The evolving proposals for revising psychotropic nomenclature to reflect pharmacology and mechanism will be investigated. Specifically, issues arising from the use of outdated “atypical antipsychotic” and “antidepressant” terminology will be explored as well as the evidence base, approvals, and indications of various psychotropic medication classes in the treatment of mood disorders. After taking part in this educational activity, it is hoped that attendees will become a part of the nomenclature solution by ceasing use of antiquated terms and adopting updated, neuroscience-centered psychotropic nomenclature.
Learning Objectives
Faculty
Joseph F. Goldberg, MD Clinical Professor, Department of Psychiatry |
Supported by
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.
Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: The presence of mixed features in unipolar and bipolar depression worsens prognosis and can have dire consequences, including greater risk of suicidality, if not diagnosed and treated in a timely and appropriate manner. In this presentation, Dr. Joseph Goldberg discusses strategies for accurately identifying mixed features and appropriate treatment strategies with the largest evidence base for efficacy in treating depression when mixed features are present.
Learning Objectives
Faculty
Joseph F. Goldberg, MD Clinical Professor, Department of Psychiatry |
Supported by
This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.
|
Industry Showcases |
Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: Managing schizophrenia presents numerous challenges, including the need to address various symptom domains. This presentation will explore ongoing research and data-driven trends in adjunctive treatment approaches and examine the underlying pathophysiology across neurotransmitter systems that may contribute to the symptoms of schizophrenia.
Learning Objectives
Faculty
Austin Campbell, PharmD, BCPP, FAAPP Clinical Associate Professor |
Supported by
This activity is supported by Bristol Myers Squibb
Break refreshments will be served from 4:30-4:45 PM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: This workshop will explore the pending changes in Clozapine REMS, providing psychiatric pharmacists with essential knowledge on the appropriate use of clozapine and the critical role of the therapeutic drug monitoring (TDM) in optimizing patient outcomes. Participants will gain practical insights into navigating regulatory updates and enhancing clinical decision-making.
Learning Objectives
Faculty
Megan Ehret, PharmD, MS, BCPP, FAAPP Professor |
|
Deanna L. Kelly, PharmD, BCPP Dr. William and Carol Carpenter Professor in Psychiatry for Mental Illness Research |
|
Robert O. Cotes, MD, DFAPA Professor and Distinguished Physician |
Supported by
This activity is supported by Saladax Biomedical, Inc.
Breakfast will be served from 7:00-7:15 AM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: Don't miss this opportunity to learn about COBENFY as a treatment option for your patients. Explore COBENFY's clinical profile, including efficacy, safety, and dosing information. This program also highlights practical considerations when prescribing COBENFY.
Learning Objectives
Faculty
Alberto Augsten, PharmD, MS, BCPP, DABAT Pharmacy Clinical Manager, Long-Acting Therapy Clinic (LAT) Manager, PGY2 Psychiatric Pharmacy Residency Director, Board Certified Clinical Toxicologist |
Supported by
This activity is supported by Bristol Myers Squibb
Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.
Overview: Discover the transformative potential of prescription digital therapeutics (PDTs), including a deep dive into the evidence supporting these technologies as effective treatments for patients with serious mental illnesses. In this industry showcase, distinguished faculty with expertise in the development and implementation of digital technologies into healthcare systems will discuss the evaluation of digital therapies in clinical trials and real-world studies in mental health conditions and how they may be implemented into practice.
Learning Objectives
Faculty
Kari Franson, PharmD, PhD, BCPP Senior Associate Dean for Academic and Student Affairs & Professor of Clinical Pharmacy |
|
Lisa Marsch, PhD Director for the Dartmouth Center for Technology and Behavioral Health (CTBH) |
|
Nathaniel Rickles, PharmD, PhD, BCPP Associate Dean of Admissions and Student Affairs |
Supported by
This activity is supported by Boehringer Ingelheim